| abstract |
REFERS TO COMPOUNDS DERIVED FROM BENZEN-SULFONAMIDE OF FORMULA (I) WHERE R1 IS H, CARBOCYCLIC (C3-C10), ALKYL (C1-C6) OPTIONALLY SUBSTITUTED WITH HALOGEN, CN OR OH, AMONG OTHERS; R2 IS CARBOCYCLIC (C3-C10), ALKYL (C1-C6), OPTIONALLY SUBSTITUTED ALCOXYL (C1-C6), AMONG OTHERS; R3 IS H, HALOGEN OR CN; R4 IS H, ALKYL (C1-C8), CYCLOALKYL (C3-C8), AMONG OTHERS; R5 IS ALKYL (C1-C8), CYCLOALKYL (C3-C8), CYCLOALKENYL (C5-C8), AMONG OTHERS; X IS CR14 O N, WHERE R14 IS H O ALKYL (C1-C6). PREFERRED COMPOUNDS ARE: 6-CHLORO-3- [3,4-DIOXO-2 - ((R) -1-PHENYL-PROPYL-AMINO) -CYCLOBUT-1-ENYL-AMINO] -2-HYDROXY-N-METOXY- N-METHYL-BENZEN-SULFONAMIDE, 6-CHLORO-2-HYDROXY-N-METOXY-N-METHYL-3- {2 - [(R) -1- (5-METHYL-FURAN-2-IL) -PROPIL- AMINO] -3,4-DIOXO-CYCLOBUT-1-ENYL-AMINO} -BENCEN-SULFONAMIDE, 6-CHLORO-3- {3,4-DIOXO-2 - [(S) - (TETRAHYDRO-THIOFEN-3-IL ) -AMINO] -CYCLOBUT-1-ENYL-AMINO} -2-HYDROXY-N-METOXY-N-METHYL-BENZEN-SULFONAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE ANTAGONISTS OF THE CXCR2 CHEMOKIN RECEPTOR, BEING USEFUL IN THE TREATMENT OF CHRONIC PULMONARY OBSTRUCTIVE DISEASE, EMPHYSEMA, OVARY CANCER, PULMONARY FIBROSIS |